104 related articles for article (PubMed ID: 9731502)
41. T-cell receptor diversity prevents T-cell lymphoma development.
Newrzela S; Al-Ghaili N; Heinrich T; Petkova M; Hartmann S; Rengstl B; Kumar A; Jäck HM; Gerdes S; Roeder I; Hansmann ML; von Laer D
Leukemia; 2012 Dec; 26(12):2499-507. PubMed ID: 22643706
[TBL] [Abstract][Full Text] [Related]
42. Immune surveillance against a solid tumor fails because of immunological ignorance.
Ochsenbein AF; Klenerman P; Karrer U; Ludewig B; Pericin M; Hengartner H; Zinkernagel RM
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2233-8. PubMed ID: 10051624
[TBL] [Abstract][Full Text] [Related]
43. Expansion of murine cytotoxic precursors in vitro and in vivo by purified interleukin-2.
Merluzzi VJ; Last-Barney K
J Biol Response Mod; 1984 Oct; 3(5):468-74. PubMed ID: 6334134
[TBL] [Abstract][Full Text] [Related]
44. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection.
Badovinac VP; Haring JS; Harty JT
Immunity; 2007 Jun; 26(6):827-41. PubMed ID: 17555991
[TBL] [Abstract][Full Text] [Related]
45. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K; O'Mara LA; Allen PM
Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
[TBL] [Abstract][Full Text] [Related]
46. Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy.
Kanagawa N; Yanagawa T; Nakagawa T; Okada N; Nakagawa S
Cancer Gene Ther; 2013 Jan; 20(1):57-64. PubMed ID: 23175243
[TBL] [Abstract][Full Text] [Related]
47. Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses.
Probst HC; Dumrese T; van den Broek MF
J Immunol; 2002 Jun; 168(11):5387-91. PubMed ID: 12023329
[TBL] [Abstract][Full Text] [Related]
48. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.
Wilde S; Sommermeyer D; Frankenberger B; Schiemann M; Milosevic S; Spranger S; Pohla H; Uckert W; Busch DH; Schendel DJ
Blood; 2009 Sep; 114(10):2131-9. PubMed ID: 19587379
[TBL] [Abstract][Full Text] [Related]
49. High-avidity T cells are preferentially tolerized in the tumor microenvironment.
Zhu Z; Singh V; Watkins SK; Bronte V; Shoe JL; Feigenbaum L; Hurwitz AA
Cancer Res; 2013 Jan; 73(2):595-604. PubMed ID: 23204239
[TBL] [Abstract][Full Text] [Related]
50. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.
Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H
Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491
[TBL] [Abstract][Full Text] [Related]
51. Naïve cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: A pitfall for T cell memory studies?
Oehen S; Brduscha-Riem K
Eur J Immunol; 1999 Feb; 29(2):608-14. PubMed ID: 10064077
[TBL] [Abstract][Full Text] [Related]
52. TCR gamma delta cells--minor redundant T cell subset or specialized immune system component?
Bluestone JA; Matis LA
J Immunol; 1989 Mar; 142(6):1785-8. PubMed ID: 2646373
[No Abstract] [Full Text] [Related]
53. Antitumor progenitor exhausted CD8
Lan X; Mi T; Alli S; Guy C; Djekidel MN; Liu X; Boi S; Chowdhury P; He M; Zehn D; Feng Y; Youngblood B
Nat Immunol; 2024 Jun; 25(6):1046-1058. PubMed ID: 38816618
[TBL] [Abstract][Full Text] [Related]
54. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.
Kaluza KM; Kottke T; Diaz RM; Rommelfanger D; Thompson J; Vile R
Hum Gene Ther; 2012 Oct; 23(10):1054-64. PubMed ID: 22734672
[TBL] [Abstract][Full Text] [Related]
55. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.
Nguyen LT; Elford AR; Murakami K; Garza KM; Schoenberger SP; Odermatt B; Speiser DE; Ohashi PS
J Exp Med; 2002 Feb; 195(4):423-35. PubMed ID: 11854356
[TBL] [Abstract][Full Text] [Related]
56. Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.
Banerjee A; Thyagarajan K; Chatterjee S; Chakraborty P; Kesarwani P; Soloshchenko M; Al-Hommrani M; Andrijauskaite K; Moxley K; Janakiraman H; Scheffel MJ; Helke K; Armenson K; Palanisamy V; Rubinstein MP; Mayer EG; Cole DJ; Paulos CM; Christina-Voelkel-Johnson ; Nishimura MI; Mehrotra S
Cancer Res; 2016 Sep; 76(18):5229-5240. PubMed ID: 27466285
[TBL] [Abstract][Full Text] [Related]
57. A method for the generation of TCR retrogenic mice.
Kieback E; Hilgenberg E; Fillatreau S
Methods Mol Biol; 2014; 1193():117-26. PubMed ID: 25151002
[TBL] [Abstract][Full Text] [Related]
58. [Effect of an operation on the immunoreactivity indices, their postoperative dynamics and the effect of 3-HAA-antigen on these indices in patients with gastrointestinal tumors].
Korosteleva TA; Pavlov KA; Mel'nikov RA; Saprin AN; Belokhvostova AT
Vopr Onkol; 1985; 31(6):52-60. PubMed ID: 4024547
[TBL] [Abstract][Full Text] [Related]
59. Targeting self-antigens through allogeneic TCR gene transfer.
de Witte MA; Coccoris M; Wolkers MC; van den Boom MD; Mesman EM; Song JY; van der Valk M; Haanen JB; Schumacher TN
Blood; 2006 Aug; 108(3):870-7. PubMed ID: 16861342
[TBL] [Abstract][Full Text] [Related]
60. Identification of a cross-reactive self ligand in virus-mediated autoimmunity.
Ohteki T; Hessel A; Bachmann MF; Zakarian A; Sebzda E; Tsao MS; McKall-Faienza K; Odermatt B; Ohashi PS
Eur J Immunol; 1999 Sep; 29(9):2886-96. PubMed ID: 10508263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
